Đang chuẩn bị liên kết để tải về tài liệu:
OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: A role for Nck1 but not Nck2

Lapatinib is characterized as an ErbB1/ErbB2 dual inhibitor and has recently been approved for the treatment of metastatic breast cancer. In this study, we examined mechanisms associated with enhancing the activity of lapatinib via combination with other therapies. |